revenue $20.1M, net income -$26.8M. Standard BioTools to exit life-sciences tools via Treeline merger; stockholders to own 16%

Filed August 5, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 15, 2025 · ~3 min read

Key Changes

• high

  Announced all-stock merger with Treeline Biosciences (clinical-stage biopharma) on Jun 6, 2026; existing LAB stockholders will own ~16% of combined company post-close, Treeline stockholders ~84%. Treeline's management team will lead the combined entity, which will be renamed Treeline Biosciences Holdings.

  Notes: Treeline merger agreement view on EDGAR →
• high

  Company will exit current business (mass cytometry and microfluidics instrumentation) by selling or monetizing those assets; proceeds distributed to LAB stockholders via contingent value rights (CVRs) paid in combined-company stock over five years, capped at 76M shares. CVRs are unsecured and may pay nothing if assets aren't monetized.

  Risk Factors: CVR payment uncertainty verify on EDGAR →
• high

  SomaScan Business sale to Illumina closed Jan 30, 2026 for $388M net cash; recognized $172M pre-tax gain. Remaining up to $50M earnout settled in Jul 2026 for $30M cash; royalty and license agreements with Illumina terminated as part of settlement.

  Notes: SomaScan sale completion view on EDGAR →